Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi-Synthelabo Recherche
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve patients with type 2 diabetes
The first primary objective is to assess the antidiabetic effect of rimonabant (HbA1C) over a period of 6 months when prescribed in treatment-naïve type 2 diabetes patients.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of depressive symptoms in patients with major depressive disorder improved after 8 months of open treatment with SR58611A (350 mg q12)
To assess the efficacy of SR58611A 350 mg q12 compared to placebo in the prevention of relapse / recurrence of depressive symptoms, in sustained responder patients with major depressive disorder, over...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
Effect of a single oral 120 µg dose of SSR150106XB compared to placebo on the assessment of post dental surgical pain after extraction of an impacted or partially impacted third molar in 90 male and female patients – Randomized, double-blind, placebo- controlled, parallel-group study –
To assess the effect of a single oral 120 µg dose of SSR150106XB on the intensity of post dental surgery pain as compared to placebo.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by carotid artery intima-media thickness (CIMT), in overweight patients with additional risk factors
To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by CIMT.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
A placebo-controlled, double blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter (AF/AFL)
To assess the efficacy of dronedarone in preventing cardiovascular hospitalizations or death from any cause in a population of high risk patients with Atrial Fibrillation/Atrial FLutter (AF/AFL).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
Estudio abierto y multicéntrico, de cincuenta y dos semanas de duración, para evaluar la seguridad y tolerabilidad a largo plazo de SR58611A 350 mg cada 12 horas en pacientes con trastorno depresivo mayor
Evaluar la seguridad y tolerabilidad a largo plazo de SR58611A en pacientes con trastorno depresivo mayor (MDD).
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2